Analysis shows increased healthcare costs in non-transfusion-dependent thalassemia, suggesting a need for better treatments.
Patients with NTDT in the United States, including those with α- and β-thalassemia, have significantly higher all-cause HCRU and costs vs. matched controls. There is a need for effective treatment options to reduce the healthcare burden of NTDT and improve patient outcomes.
No takes yet. Share an insight, caveat, or question.
Langer et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: